FDA approves US WorldMeds’s iwilfin for neuroblastoma
The US FDA granted approval for US WorldMeds’ iwilfin for use as an oral maintenance treatment for high-risk neuroblastoma.
The US FDA granted approval for US WorldMeds’ iwilfin for use as an oral maintenance treatment for high-risk neuroblastoma.
What's Your Reaction?
